Sign In
Buy PRTA
$8.12
-0.290 (-3.45%)
At Close: Jul 31, 2026
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
12:56pm, Thursday, 09'th May 2024
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
07:11pm, Wednesday, 08'th May 2024
Prothena (PRTA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $0.89 per share a year ago.
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
11:08am, Thursday, 25'th Apr 2024
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
04:05pm, Monday, 15'th Apr 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #amyloidosis--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
Prothena to Participate in Upcoming Healthcare Conferences
04:05pm, Tuesday, 05'th Mar 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in March.
Prothena Appoints David Ford to Newly Created Chief People Officer Position
04:05pm, Monday, 04'th Mar 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it has named David Ford to a newly created position of Chief People Officer.
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
04:05pm, Wednesday, 21'st Feb 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate.
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
02:36pm, Friday, 16'th Feb 2024
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
11:53pm, Thursday, 15'th Feb 2024
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
04:05pm, Thursday, 15'th Feb 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the fourth quarter and full year 2023.
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
04:05pm, Thursday, 08'th Feb 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that it will report its 4th quarter and full year 2023 financial results on February 15, 2024 after close of U.S. financial markets.
Prothena's (PRTA) Update on Pipeline Progress Disappoints
01:32pm, Wednesday, 10'th Jan 2024
Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
06:46am, Wednesday, 10'th Jan 2024
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
08:30am, Monday, 08'th Jan 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena provided a business update on portfolio programs.
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
10:32am, Monday, 11'th Dec 2023
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
